Breast cancer molecular subtypes as identified by immunohistochemistry in South African black women

Breast Journal

Volumn 19, Issue 2, 2013, Pages 210-211

  Van Bogaert, Louis Jacques ^a  

^a UNIVERSITY OF LIMPOPO   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKERATIN 5; CYTOKERATIN 6; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

BREAST CANCER; CANCER PROGNOSIS; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LETTER; MOLECULAR BIOLOGY; NEGRO; PROTEIN EXPRESSION; SOUTH AFRICA;

AFRICAN CONTINENTAL ANCESTRY GROUP; BREAST NEOPLASMS; COHORT STUDIES; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KERATIN-5; KERATIN-6; PROSPECTIVE STUDIES; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SOUTH AFRICA;

EID: 84874753069     PISSN: 1075122X     EISSN: 15244741     Source Type: Journal    
DOI: 10.1111/tbj.12090     Document Type: Letter

References (16)

1. Smigal C, Jemal A, Ward E, et al,. Trends in breast cancer by race and ethnicity: update 2006. CA Cancer J Clin 2006; 56: 168-83.
2. Carey LA, Perou CM, Livasy CA, et al,. Race, breast cancer subtypes, and survival in the Carolina breast cancer study. JAMA 2006; 295: 2492-502.
3. Ihemelandu CU, Lefall LD Jr, Dewitty RL, et al,. Molecular breast cancer subtypes in premenopausal and postmenopausal African-American women: age-specific prevalence and survival. J Surg Res 2007; 143: 109-18.
4. Stead LA, Lash TL, Sobieraf JE, et al,. Triple-negative breast cancers are increased in black women regardless of age or body mass index. Breast Cancer Res 2009; 11: R18.
5. Fregene A, Newman LA,. Breast cancer in sub-Saharan Africa: how does it relate to breast cancer in African-American women? Cancer 2005; 103: 1540-50.
6. Rakha EA, Elsheikh SE, Aleskandarany MA, et al,. Triple-negative breast cancer: distinguishing between basal and non-basal subtypes. Clin Cancer Res 2009; 15: 2302-10.
7. Allred DC, Harvey JM, Berardo M, et al,. Prognostic and predictive factors in breast cancer by immunohistochemistry. Mod Pathol 1998; 11: 155-68.
8. Wolff A, Hammond ME, Schwarz JN, et al,. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor 2 testing in breast cancer. J Clin Oncol 2007; 25: 118-45.
9. Gorsching E, Jeffrey SS, Meinerz W, et al,. Basal carcinoma of the breast revisited: an old entity with new interpretations. J Clin Pathol 2008; 61: 553-60.
10. Pegoraro RM, Karnan V, Nirmul D, et al,. Estrogen and progesterone receptors in breast cancer among women of different racial groups. Cancer Res 1986; 46: 2117-20.
11. Mbonde MP, Amir H, Schwartz-Albiez R, et al,. Expression of estrogen and progesterone receptors in carcinomas of the female breast in Tanzania. Oncol Rep 2000; 7: 277-83.
12. Ikpatt OF, Ndoma-Egba R,. Oestrogen and progesterone receptors in Nigerian breast cancer: relationship to tumour histopathology and survival of patients. Centr Afr J Med 2003; 49: 122-6.
13. Bird PA, Hill AG, Houssami N,. Poor hormone receptor expression in East African breast cancer: evidence of a biologically different disease? Ann Surg Oncol 2008; 15: 1983-8.
14. Nyagol J, Nyonglo A, Buyakika B, et al,. Routine assessment of hormonal receptor and her-2/neu status underscores the need for more therapeutic targets in Kenyan women with breast cancer. Anal Quant Cytol Histol 2006; 28: 97-103.
15. Adebamowo CA, Famooto A, Oqundiran TO, et al,. Immunohistochemical and molecular subtypes of breast cancer in Nigeria. Breast Cancer Res Treat 2008; 110: 183-8.
16. Trinkaus ME, Sayed S, Gakinya AM, et al,. Triple negative and basal-like breast cancer in East Africa. The Breast J 2011; 17: 438-40.